Adempas (Riociguat Tablets) is a soluble guanylate cyclase stimulant, primarily indicated for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).

How to Purchase Adempas (Riociguat Tablets)

Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or legitimate drugstores in countries or regions where Adempas has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budget and plans in advance before purchasing.

Purchase through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and can offer professional consultation and guidance.

Precautions for Purchase and Use of Adempas (Riociguat Tablets)

Absolute Contraindicated Populations

Pregnant women.

Patients concurrently using nitrates or nitric oxide donors.

Patients using phosphodiesterase inhibitors.

Patients concurrently using other soluble guanylate cyclase stimulants.

Patients with pulmonary arterial hypertension associated with idiopathic interstitial pneumonia.

Special Risk Warnings

Embryotoxicity Risk: The drug poses a teratogenic risk to the fetus. Pregnancy must be excluded before starting medication, and effective contraceptive measures must be consistently used during treatment.

Hypotension Risk: The drug can lower blood pressure; special caution is required for patients with hypovolemia, severe left ventricular outflow tract obstruction, etc.

Bleeding Risk: Clinical trials show that the incidence of severe bleeding in patients taking Adempas is 2.4%.

Medication for Special Populations

Renal Impairment: Not recommended for patients with creatinine clearance < 15 mL/min or those receiving dialysis.

Hepatic Impairment: Not recommended for patients with severe hepatic impairment.

Smoking Patients: Dosage adjustment may be required; plasma concentrations in smokers are 50%-60% lower than those in non-smokers.

How to Identify the Authenticity of Adempas (Riociguat Tablets)

Identification by Appearance Characteristics

0.5mg: White film-coated tablets, engraved with the "BAYER" cross logo on one side, and "0.5" and "R" on the other side.

1mg: Light yellow film-coated tablets, engraved with the "BAYER" cross logo on one side, and "1" and "R" on the other side.

1.5mg: Yellow-orange film-coated tablets, engraved with the "BAYER" cross logo on one side, and "1.5" and "R" on the other side.

2mg: Light orange film-coated tablets, engraved with the "BAYER" cross logo on one side, and "2" and "R" on the other side.

2.5mg: Red-orange film-coated tablets, engraved with the "BAYER" cross logo on one side, and "2.5" and "R" on the other side.

Verification of Packaging Markings

Clear batch number and expiration date.

Complete package insert.

Anti-counterfeiting marks and REMS (Risk Evaluation and Mitigation Strategy) program certification information.